Healthcare -
Biotechnology - NASDAQ - IL
$ 3.91
0.256 %
$ 273 M
Market Cap
-9.09
P/E
1. INTRINSIC VALUE
Balance Sheet
Alpha Tau Medical Ltd.
| Current Assets | 85.8 M |
| Cash & Short-Term Investments | 81.8 M |
| Receivables | 19 K |
| Other Current Assets | 3.95 M |
| Non-Current Assets | 21.6 M |
| Long-Term Investments | 0 |
| PP&E | 21.2 M |
| Other Non-Current Assets | 471 K |
| Current Liabilities | 7.1 M |
| Accounts Payable | 2.57 M |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.47 M |
| Non-Current Liabilities | 15.8 M |
| Long-Term Debt | 12.2 M |
| Other Non-Current Liabilities | 3.6 M |
EFFICIENCY
Earnings Waterfall
Alpha Tau Medical Ltd.
| Revenue | 0 |
| Cost Of Revenue | 1.07 M |
| Gross Profit | -1.07 M |
| Operating Expenses | -35.7 M |
| Operating Income | 35.7 M |
| Other Expenses | 64.8 M |
| Net Income | -29.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alpha Tau Medical Ltd.
| Net Income | -29.2 M |
| Depreciation & Amortization | 1.07 M |
| Capital Expenditures | -6.4 M |
| Stock-Based Compensation | 7.93 M |
| Change in Working Capital | 2.49 M |
| Others | 9.99 M |
| Free Cash Flow | -24.4 M |
Wall Street Analysts Price Targets
Alpha Tau Medical Ltd.
Wall Street analysts predict an average 1-year price target for DRTS of $7 , with forecasts ranging from
a
low of
$7 to a high of $7 .
DRTS Lowest Price Target
Wall Street Target
7 USD
79.03%
DRTS Average Price Target
Wall Street Target
7 USD
79.03%
DRTS Highest Price Target
Wall Street Target
7 USD
79.03%
4. DIVIDEND
ANALYSIS
DRTS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Alpha Tau Medical Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma,” submitted by principal investigators involved in the Company's Israeli pancreatic cancer trial, has been accepted to the 2025 ASCO Gastrointestinal Cancers Symposium, to be held January 23 – 25, 2025 in San Francisco, CA. The poster will be presented during “Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract,” on January 24, 2025 at 11:30am – 1:00pm PT.
globenewswire.com
- 1 month ago
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors (“Board”). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity.
globenewswire.com
- 1 month ago
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones
globenewswire.com
- 1 month ago
Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium.
globenewswire.com
- 1 month ago
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference
JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the Citi 2024 Global Healthcare Conference on December 3rd, 2024 and the Piper Sandler 36th Annual Healthcare Conference on December 5th, 2024.
globenewswire.com
- 2 months ago
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) Pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme (“GBM”). This acceptance follows the Company's previous receipt of Breakthrough Device Designation from the FDA for this indication, one of two such designations received for the Alpha DaRT, and a pre-requisite for application to the TAP program.
globenewswire.com
- 2 months ago
Alpha Tau Treats First Patient with Recurrent Lung Cancer
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that its first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.
globenewswire.com
- 3 months ago
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - -Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population -
globenewswire.com
- 3 months ago
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024.
globenewswire.com
- 4 months ago
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an overall response rate of almost 100% in treated le sions , no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - - Cash, cash equivalents & deposits balance of $ 74.1 million with runway of at least two years - JERUSALEM, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported second quarter 2024 financial results and provided a corporate update.
globenewswire.com
- 5 months ago
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity.
globenewswire.com
- 6 months ago
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024.
globenewswire.com
- 7 months ago
8. Profile
Summary
Alpha Tau Medical Ltd. DRTS
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 273 M
Dividend Yield
0.00%
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Contact
5 Kiryat Hamada Street, Jerusalem, 9777605
https://www.alphatau.com
IPO
Date
March 8, 2021
Employees
121
Officers
Prof. Yona Keisari
Chief Scientific Officer & Member of Scientific Advisory board
Mr. Ronen Segal
Chief Technology Officer
Prof. Itzhak Kelson
Chief Physics Officer & Member of Scientific Advisory Board
Ms. Yael Zeiger
Corporate Controller
Mr. Amnon Gat
Chief Operations Officer
Mr. Raphi Levy
Chief Financial Officer
Mr. Peter M. Melnyk
Chief Commercial Officer
Ms. Rebecca Becker
Vice President of legal
Dr. Robert B. Den M.D.
Chief Medical Officer & Member of Scientific Advisory Board
Mr. Uzi Sofer
Chief Executive Officer & Chairman